05.26.26 -- Why Material Definitions Matter In Cell And Gene Therapy

Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

Examine how evolving regulatory standards impact cell therapy shipping systems. Industry leaders detail essential compliance frameworks necessary for maintaining an optimized supply chain.

A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

Single-use bioreactors with turndown ratios up to 20:1 enable facilities to operate across wide volume ranges within the same vessel, streamlining seed trains and reducing capital requirements for multi-product operations.

Learn about a system that uses a gentle elutriation process to give manufacturers a cleaner cell population to begin cell therapy production processes such as CAR-T.

In this segment of Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, with host Erin Harris, discuss why cell and gene therapy, clearly defining raw, starting, and ancillary materials, and using those terms consistently, is critical.

See a validated, end-to-end protocol for producing high-quality in vitro transcription (IVT) mRNA for preclinical research. Find out how to optimize sequence design, small-scale synthesis, and more.